This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Phlebotomy is the mainstay of treatment in patients with homozygous hereditary hemochromatosis and evidence of iron overload

  • the aim is to keep blood ferritin values <50-100 μg/L
  • it is indicated in all patients with ferritin values >1000 μg/L.
    • a meta analysis has reported that levels more than 1000 μg/L may result in liver cirrhosis
    • initially carried out once a week or fortnightly
  • with moderately raised ferritin levels (200-1000 μg/L), initiation of phlebotomy depends on patient preference and clinical judgment
  • C282Y homozygotes without evidence for iron overload could be monitored annually and treatment instituted when the ferritin rises above normal
  • 400-500 mL is usually removed (which depletes 200-250 g of iron)
    • the volume and frequency may be adjusted according to the degree of iron overload and baseline haemoglobin values.
  • haemoglobin and ferritin levels must be monitored regularly
    • maintenance phlebotomy should be arranged when ferritin levels drops to 50-100 μg/L – usually every two to four months
  • before the initiation of phlebotomy, patients with HFE-HC should be assessed for complications including diabetes mellitus, joint disease, endocrine deficiency (hypothyroidism), cardiac disease, porphyria cutanea tarda, and osteoporosis
  • phlebotomy has been shown to prevent further tissue damage, decreased fatigue, improved skin hyperpigmentation, and reduced early hepatic fibrosis and left ventricular dysfunction
    • there is usually no improvement in arthropathy and testicular atrophy after phlebotomy
    • the risk of hepatocellular carcinoma is not decreased after adequate phlebotomy in patients with cirrhosis, hence screening for hepatocellular carcinoma must continue
  • dietary iron restriction is not necessary when undergoing phlebotomy
    • iron and vitamin C supplementation should be avoided
  • alcohol restriction is also advised. Due to the increased risk of infection with Vibrio vulnificus, uncooked seafood should be avoided
  • to minimize the risk of additional complications, patients with HFE-HC could be immunized against hepatitis A and B while iron overloaded
  • vigorous physical activity should be avoided for 24 h after phlebotomy (1,2,3,4)

Iron chelation therapy can be used as a second line option in patients who are intolerant of phlebotomy.

  • deferoxamine or deferasirox is used
  • clinical data on their use in hereditary haemochromatosis are limited (1,2,3,4,5,6)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.